Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

20151,086 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 16, Issue 13, pp. 1344-1354

Field-Weighted Citation Impact: 45.87